Vascular endothelial growth factor receptor-1 contributes to resistance to anti - epidermal growth factor receptor drugs in human cancer cells

Clinical Cancer Research

Volumn 14, Issue 16, 2008, Pages 5069-5080

  Bianco, Roberto ^a   Rosa, Roberta ^a   Damiano, Vincenzo ^a   Daniele, Gennaro ^a   Gelardi, Teresa ^a   Garofalo, Sonia ^a   Tarallo, Valeria ^b   De Falco, Sandro ^b   Melisi, Davide ^a   Benelli, Roberto ^d   Albini, Adriana ^e   Ryan, Anderson ^f   Ciardiello, Fortunato ^c   Tortora, Giampaolo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b INSTITUTE OF GENETICS AND BIOPHYSICS ADRIANO BUZZATI TRAVERSO   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

^e IRCCS MULTIMEDICA   (Italy)

^f ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; P70S6 KINASE; PHOSPHOTRANSFERASE; PLACENTAL GROWTH FACTOR; PROTEIN KINASE B; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; ANTINEOPLASTIC AGENT; N (4 BROMO 2 FLUOROPHENYL) 6 METHOXY 7 ((1 METHYLPIPERIDIN 4 YL)METHOXY)QUINAZOLIN 4 AMINE; N-(4-BROMO-2-FLUOROPHENYL)-6-METHOXY-7-((1-METHYLPIPERIDIN-4-YL)METHOXY)QUINAZOLIN-4-AMINE; PIPERIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE;

APOPTOSIS; ARTICLE; CANCER CELL; CELL ADHESION; CELL MIGRATION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; SENSITIVITY ANALYSIS; WILD TYPE; CELL MOTION; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; GENETIC TRANSFECTION; IMMUNOPRECIPITATION; METABOLISM; NEOPLASM; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR CELL LINE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOPRECIPITATION; NEOPLASMS; PIPERIDINES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 52649143725     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4905     Document Type: Article

References (52)

1. Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 2006;7:505-16.
2. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005;5:341 -54.
3. Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol 2006:33:369-85.
4. Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 2005;23:2445-59.
5. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008:358:1160-74.
6. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76.
7. Shibuya M. Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogene-sis. J Biochem Mol Biol 2006;39:469-78.
8. Fan F, Wey JS, McCarty MF, et al. Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells. Oncogene 2005;24:2647-53.
9. Liu B, Earl HM, Baban D. Melanoma cell lines express VEGF receptor KDR and respond to exogenously added VEGF, Biochem Biophys Res Commun 1995;217:721-7.
10. Strizzi L, Catalano A, Vianale G. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol 2001;193:468-75.
11. Fontanini G.Vignati S, Boldrini L, et al. Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. Clin Cancer Res 1997;3:861-5.
12. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007;6:273-86.
13. Melillo G. Targeting hypoxia cell signaling for cancer therapy. Cancer Metastasis Rev 2007;26:341-52.
14. Goldman CK, Kim J.Wong WL, King V, Brock T, Gillespie GY. Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol Biol Cell 1993:4:121-33.
15. Gille J, Swerlick RA, Caughman SW. Transforming growth factor α-induced transcriptional activation of the vascular permeability factor (VPF/VEGF) gene requires AP2-dependent DNA binding and transacti-vation. EMBO J 1997;16:750-9.
16. Perrotte P, Matsumoto T, Inoue K, et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res1999;5:257-65.
17. Ciardiello F, Bianco R, Damiano V, et al. Antiangio-genic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor anti-sense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res 2000;6:3739-47.
18. Bruns CJ, Solorzano CC, Harbison MT et al. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 2000;60:2926-35.
19. Ciardiello F, Caputo R, Bianco R, et al. Inhibition of growth factor production and angiogenesis in human Cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 2001;7:1459-65.
20. ByzovaTV, Goldman CK, Pampori N, et al. A mechanism for modulation of cellular responses to VEGF:activation of the integrins. Mol Cell 2000:6:851-60.
21. Dias S, Shmelkov SV, Lam G, Rafii S. VEGF(165) promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition. Blood 2002;99:2532-40.
22. Lyden D, Hattori K, Dias S, et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Rev 2001;7:1194-201.
23. LuY, Zi X, ZhaoY, Mascarenhas D, Pollak M. Insulinlike growth factor-l receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst (Bethesda) 2001;93:1852-7.
24. Viloria-Petit A, CrombetT Jothy S, et al. Acquired resistance to the antitumor activity of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res 2001;61:5090-101.
25. Chakravarti A, Loeffler JS, Dyson NJ. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling Cancer Res 2002;62:200-7.
26. Ciardiello F, Bianco R, Caputo R, et al. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to anti-epidermal growth factor receptor therapy. Clin Cancer Res 2004;10:784-93.
27. Vallbohmer D, Zhang W, Gordon M, et al. Molecular determinants of cetuximab efficacy. J Clin Oncol 2005;23:3536-44.
28. Ellis LM. Epidermal growth factor receptor in tumor angiogenesis. Hematol Oncol Clin North Am 2004;18:1007-21.
29. Wedge SR. Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002;62:4645-55.
30. Carlomagno F.Vitagliano D, GuidaT, et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 2002;62:7284-90.
31. Herbst RS, Heymach JV, O'Reilly MS, Onn A, Ryan AJ. Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. Expert Opin Investig Drugs 2007;16:239-49.
32. Melisi D, Caputo R, DamianoV, et al. Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer. Endocr Relat Cancer 2005:12:1051-8.
33. Errico M, Riccioni T, Iyer S, et al. Identification of placenta growth factor determinants for binding and activation of Flt-1 receptor. J Biol Chem 2004;279:43929-39.
34. Benelli R, Peissel B, Manenti G, et al. Allele-specific patterns of the mouse parathyroid hormone-related protein: influences on cell adhesion and migration. Oncogene 2003;22:7711-5.
35. Albini A, Benelli R. The chemoinvasion assay: a method to assess tumor and endothelial cell invasion and its modulation. Nat Protoc 2007;2:504-11.
36. Bennett RD, MauerAS, Strehler EE. Calmodulin-like protein increases filopodia-dependent cell motility via up-regulation of myosin-10. J Biol Chem 2007;282:3205-12.
37. Bianco R, Shin I, Ritter CA, et al. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 2003;22:2812-22.
38. She QB, Solit D, Basso A, Moasser MM. Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3′-kinase/Akt pathway signaling. Clin Cancer Res 2003;9:4340-6.
39. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-43.
40. Manley PW, Furet P, Bold G. Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. J Med Chem 2002;45:5687-93.
41. PaoW, MillerVA, Politi KA, etal. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:e73.
42. Shayesteh L, Lu Y, KuoWL, et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 1999;21:99-102.
43. ShienT, Doihara H, Hara H, et al. PLC and PI3K pathways are important in the inhibition of EGF-in-duced cell migration by gefitinib ('Iressa', ZD1839). Breast Cancer 2004;11:367-73.
44. Neshat MS, Mellinghoff IK.Tran C, et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A 2001;98:10314-9.
45. Morgillo F, KimWY, Kim ES, Ciardiello F, HongWK, Lee HY. Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. Clin Cancer Res 2007;13:2795-803.
46. Vitagliano D, Carlomagno F, Motti ML, etal. Regulation of p27Kip1 protein levels contributes to mito-genic effects of the RET/PTC kinase in thyroid carcinoma cells. Cancer Res 2004;64:3823-9.
47. Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH. Different signal transduction properties of KDR and Flfl, two receptors for vascular endothelial growth factor. J Biol Chem 1994:269:26988-95.
48. Hiratsuka S, Maru Y, Okada A, Seiki M, NodaT, Shibuya M. Involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis. Cancer Res 2001;61:1207-13.
49. Hasan J, Jayson GC. VEGF antagonists. Expert Opin Biol Ther 2001;1:703-18.
50. Masood R, Cai J, ZhengT Smith DL, Hinton DR, Gill PS. Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. Blood 2001;98:1904-13.
51. Lesslie DP, Summy JM, Parikh NU, et al. Vascular endothelial growth factor receptor-1 mediates migration of human colorectal carcinoma cells by activation of Src family kinases. Br J Cancer 2006;94:1710-17.
52. Kaplan RN, Ribal RD, Zacharoulis S, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005:438:820-7.